Long COVID exhibits clinically distinct phenotypes at 3-6 months post-SARS-CoV-2 infection: results from the P4O2 consortium.
Jelle M BlankestijnMahmoud I Abdel-AzizNadia BaalbakiSomayeh BazdarInés BeekersRosanne J H C G BeijersLizan D BloemsmaMerel E B CornelissenDebbie GachLaura HouwelingSebastiaan HolverdaJohn J L JacobsReneé JonkerIvo van der LeePaulien M A LindersFirdaus A A Mohamed HoeseinLieke C E NoijEsther J NossentMarianne A van de PolDaphne W SchamineeAnnemie M W J ScholsLisanne T SchuurmanBrigitte SondermeijerJ J Miranda GeelhoedJoop P van den BerghEls J M WeersinkYolanda de Wit-van WijckAnke H Maitland-van der Zeenull nullPublished in: BMJ open respiratory research (2024)
Long COVID patients can be clustered into three distinct phenotypes based on their clinical presentation and easily obtainable information. These clusters show distinction in patient characteristics, lung function, long COVID severity and acute SARS-CoV-2 infection severity. This clustering can help in selecting the most beneficial monitoring and/or treatment strategies for patients suffering from long COVID. Follow-up research is needed to reveal the underlying molecular mechanisms implicated in the different phenotypes and determine the efficacy of treatment.
Keyphrases
- sars cov
- coronavirus disease
- lung function
- respiratory syndrome coronavirus
- end stage renal disease
- cystic fibrosis
- air pollution
- chronic obstructive pulmonary disease
- chronic kidney disease
- newly diagnosed
- single cell
- ejection fraction
- liver failure
- peritoneal dialysis
- case report
- healthcare
- prognostic factors
- gene expression
- rna seq
- drug induced
- patient reported outcomes
- health information
- dna methylation
- combination therapy
- smoking cessation